CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ | $0.4846 96K

(0.0% 1d) (-14.6% 1m) (-86.4% 1y) (0.0% 2d) (0.0% 3d) (-4.5% 7d) (259.91% volume)
Earnings Calendar:
Market Cap: $ 6,821,349
https://creativemedicaltechnology.com
Sec Filling | Patents | n/a employees

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company committed to improving patient lives in the areas of Immunology, Urology, Neurology and Orthopedics. Creative Medical Technology Holdings, Inc. is focused on regenerative medical solutions for unmet Immunological, Urological, Neurological and Orthopedic needs. The company has developed an extensive intellectual property portfolio utilizing stem cells and interrelated technologies for the treatment of multiple indications and commercialized complete patented and trademarked protocols for erectile dysfunction under the CaverStem® brand and the FemCelz® brand for the treatment of female sexual dysfunction. Its StemSpine® technology has undergone a pilot study and is prepared for commercialization of it’s autologous (patients own stem cells) program with the vision of progressing it’s patented allogenic (donor cells) program through FDA clinical trial. CELZ is also breaking new ground with its ImmCelz® technology for the treatment of multiple indications. Its team consists of leading physicians and scientists specializing in regenerative medicine. Its "science-first" approach to procedures ensures that all of its technology is proven to be both safe and effective.

treatment urea brands t-cell

add to watch list email alert is off

Press-releases

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
CELZ | $0.4846 96K

| -22.03% | O: 1.56% H: 0.0% C: -6.18%
SYNH | $35.97 1.38% 110K

Health Services

| -12.06% | O: 0.03% H: 0.45% C: -1.01%
celz-201 medical technology trial diabetes international phase 1

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects
Published: 2023-02-14 (Crawled : 16:00) - biospace.com/
CELZ | $0.4846 96K

| -32.0% | O: 4.37% H: 0.0% C: 0.0%
stemspine year back

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes
Published: 2022-11-03 (Crawled : 12:20) - biospace.com/
CELZ | $0.4846 96K

| 17.69% | O: 13.21% H: 41.67% C: 4.17%
treatment fda clearance drug application technology diabetes therapy

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line
Published: 2022-10-20 (Crawled : 12:20) - prnewswire.com
CELZ | $0.4846 96K

| 27.95% | O: 5.08% H: 10.3% C: 0.39%
technology

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study
Published: 2022-09-26 (Crawled : 16:00) - biospace.com/
CELZD | $4.8 0%

n/a

| Email alert Add to watchlist
CELZ | $0.4846 96K

| Email alert Add to watchlist
stemspine technology positive publication study

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study
Published: 2022-07-28 (Crawled : 12:00) - prnewswire.com
CELZ | $0.4846 96K

| -25.99% | O: 8.72% H: 4.5% C: 0.68%
ovastem technology positive study

Global Exosome Research Markets 2022-2026 - Opportunities in Untapped Emerging Markets, Growing Interest in Exosome-based Therapeutics, & High Demand for Personalized Medicine
Published: 2022-05-23 (Crawled : 11:00) - prnewswire.com
CELZ | $0.4846 96K

| -51.08% | O: -1.96% H: 8.0% C: 1.0%
QGEN | $45.66 0.07% 170K

Health Technology

| 1.21% | O: 1.01% H: 0.33% C: 0.13%
QGEN | $45.66 0.07% 170K

Health Technology

| 1.21% | O: 1.01% H: 0.33% C: 0.13%
AEMD | $0.3786 7.4K

Health Technology

| -71.02% | O: -1.54% H: 34.38% C: 25.78%
research growing

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Published: 2022-04-29 (Crawled : 13:00) - prnewswire.com
CELZ | $0.4846 96K

| -75.05% | O: -5.0% H: 5.79% C: -1.05%
nasdaq technology

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product
Published: 2022-04-20 (Crawled : 14:00) - biospace.com/
CELZ | $0.4846 96K

| -77.72% | O: 7.59% H: 14.11% C: 1.66%
immcelz technology

Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution™ Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction
Published: 2022-03-10 (Crawled : 18:00) - biospace.com/
CELZ | $0.4846 96K

| -68.01% | O: -0.64% H: 9.03% C: 5.16%
ema fun ces distribution device technology cel

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001477932-22-007311	4	2022-09-29	2022-09-27	Buy	P	2000	18502
0001477932-22-007299	4	2022-09-28	2022-09-27	Buy	P	20000	87087